Cargando…
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
BACKGROUND: The aim of the study was to analyze the relationship between pretreatment inflammatory biomarkers (IBs) and survival outcomes for patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (neo‐CRT) and pembrolizumab. METHODS: Clinical variables an...
Autores principales: | Qi, Wei‐Xiang, Wang, Xiaoyan, Li, Chengqiang, Li, Shuyan, Li, Huan, Xu, Feifei, Chen, Jiayi, Zhao, Shengguang, Li, Hecheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260499/ https://www.ncbi.nlm.nih.gov/pubmed/37089116 http://dx.doi.org/10.1111/1759-7714.14898 |
Ejemplares similares
-
Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design
por: Zheng, Yuyan, et al.
Publicado: (2021) -
Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy)
por: Cao, Yuqin, et al.
Publicado: (2022) -
The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020) -
Absolute Lymphocyte Count in Preoperative Chemoradiotherapy for Rectal Cancer: Changes Over Time and Prognostic Significance
por: Oh, Seung Yeop, et al.
Publicado: (2018) -
External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
por: Brinkmann, Sebastian, et al.
Publicado: (2019)